Do analysts prefer AMRN or CAPR?

Capricor Therapeutics has a consensus target price of $53.67, suggesting a potential upside of 175.21%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Capricor Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Do analysts rate AMRN or MGTX?

MeiraGTx has a consensus price target of $26.00, suggesting a potential upside of 112.94%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 MeiraGTx 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings & valuation, AMRN or MGTX?

Amarin has higher revenue and earnings than MeiraGTx. Amarin is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.33 -$38.80M -$0.65 N/A MeiraGTx $81.39M 13.89 -$114.20M -$1.48 N/A

Is AMRN or MGTX more profitable?

Amarin has a net margin of -15.51% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% MeiraGTx -151.12% N/A -54.96%

Does the media refer more to AMRN or MGTX?

In the previous week, Amarin had 2 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Amarin and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Amarin's score of -0.21 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AMRN or SVRA?

Savara has a consensus target price of $10.14, suggesting a potential upside of 84.75%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Savara 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has stronger valuation and earnings, AMRN or SVRA?

Amarin has higher revenue and earnings than Savara. Amarin is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.33 -$38.80M -$0.65 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is AMRN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Savara N/A -87.19% -66.42%

Do analysts recommend AVLN or AMRN?

Avalyn Pharma presently has a consensus price target of $59.00, suggesting a potential upside of 106.08%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalyn Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer AVLN or AMRN?

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.64 beat Amarin's score of -0.21 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SDGR or AMRN?

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 35.00%. Given Schrodinger's higher probable upside, equities research analysts plainly believe Schrodinger is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, SDGR or AMRN?

Amarin has lower revenue, but higher earnings than Schrodinger. Amarin is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $255.87M 4.33 -$103.26M -$1.41 N/A Amarin $213.65M 1.33 -$38.80M -$0.65 N/A

Is SDGR or AMRN more profitable?

Amarin has a net margin of -15.51% compared to Schrodinger's net margin of -40.61%. Amarin's return on equity of -2.99% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Schrodinger -40.61% -30.85% -15.32% Amarin -15.51% -2.99% -2.07%

Does the media prefer SDGR or AMRN?

In the previous week, Amarin had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Amarin's score of -0.21 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Amarin (AMRN) Competitors

$13.60 -0.34 (-2.44%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$13.64 +0.04 (+0.26%)

As of 07/20/2026 07:34 PM Eastern

Compare

AMRN vs. CAPR, MGTX, SVRA, AVLN, and SDGR

Should you buy Amarin stock or one of its competitors? MarketBeat compares Amarin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amarin include Capricor Therapeutics (CAPR), MeiraGTx (MGTX), Savara (SVRA), Avalyn Pharma (AVLN), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

How does Amarin compare to Capricor Therapeutics?

Amarin (NASDAQ:AMRN) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Amarin had 3 more articles in the media than Capricor Therapeutics. MarketBeat recorded 3 mentions for Amarin and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Amarin's score of -0.21 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Neutral
Capricor Therapeutics	Positive

Capricor Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Amarin has higher revenue and earnings than Capricor Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Amarin has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Capricor Therapeutics has a consensus target price of $53.67, suggesting a potential upside of 175.21%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

22.3% of Amarin shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Amarin beats Capricor Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Amarin compare to MeiraGTx?

Amarin (NASDAQ:AMRN) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Amarin has a net margin of -15.51% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
MeiraGTx	-151.12%	N/A	-54.96%

MeiraGTx has a consensus price target of $26.00, suggesting a potential upside of 112.94%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Amarin has higher revenue and earnings than MeiraGTx. Amarin is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A
MeiraGTx	$81.39M	13.89	-$114.20M	-$1.48	N/A

22.3% of Amarin shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amarin has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Amarin had 2 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Amarin and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Amarin's score of -0.21 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MeiraGTx beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Amarin compare to Savara?

Amarin (NASDAQ:AMRN) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Amarin has higher revenue and earnings than Savara. Amarin is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

22.3% of Amarin shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Savara has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Savara	N/A	-87.19%	-66.42%

Savara has a consensus target price of $10.14, suggesting a potential upside of 84.75%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, Amarin had 3 more articles in the media than Savara. MarketBeat recorded 3 mentions for Amarin and 0 mentions for Savara. Savara's average media sentiment score of 0.00 beat Amarin's score of -0.21 indicating that Savara is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Neutral
Savara	Neutral

Summary

Savara beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Amarin compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Amarin (NASDAQ:AMRN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalyn Pharma has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Avalyn Pharma's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Amarin	-15.51%	-2.99%	-2.07%

Avalyn Pharma presently has a consensus price target of $59.00, suggesting a potential upside of 106.08%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Avalyn Pharma has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.64 beat Amarin's score of -0.21 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalyn Pharma beats Amarin on 9 of the 13 factors compared between the two stocks.

How does Amarin compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Amarin had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Amarin's score of -0.21 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 35.00%. Given Schrodinger's higher probable upside, equities research analysts plainly believe Schrodinger is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Schrodinger has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Amarin has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amarin has a net margin of -15.51% compared to Schrodinger's net margin of -40.61%. Amarin's return on equity of -2.99% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Amarin	-15.51%	-2.99%	-2.07%

Amarin has lower revenue, but higher earnings than Schrodinger. Amarin is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.33	-$103.26M	-$1.41	N/A
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A

Summary

Schrodinger beats Amarin on 9 of the 17 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$292.31M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-20.92	20.49	27.07	23.94
Price / Sales	1.33	300.33	515.91	90.33
Price / Cash	38.62	60.31	26.68	47.25
Price / Book	0.62	7.92	10.43	6.14
Net Income	-$38.80M	$23.81M	$3.60B	$331.74M
7 Day Performance	-5.36%	-1.09%	-1.20%	-1.82%
1 Month Performance	-15.16%	2.56%	1.12%	-1.45%
1 Year Performance	-12.54%	42.16%	23.66%	16.32%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	1.4437 of 5 stars	$13.60 -2.4%	N/A	-14.0%	$292.31M	$213.65M	N/A	360
CAPR Capricor Therapeutics	2.8823 of 5 stars	$20.61 -4.2%	$53.67 +160.4%	+183.4%	$1.25B	$22.27M	N/A	101	Positive News
MGTX MeiraGTx	3.6471 of 5 stars	$12.34 -7.8%	$26.00 +110.7%	+41.6%	$1.24B	$81.39M	N/A	300	Gap Down
SVRA Savara	1.4601 of 5 stars	$5.74 -4.8%	$10.14 +76.7%	+142.9%	$1.24B	N/A	N/A	20	Positive News
AVLN Avalyn Pharma	4.1089 of 5 stars	$27.84 -0.8%	$59.00 +111.9%	N/A	$1.23B	N/A	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors

AMRN vs. CAPR, MGTX, SVRA, AVLN, and SDGR

How does Amarin compare to Capricor Therapeutics?

Summary

How does Amarin compare to MeiraGTx?

Summary

How does Amarin compare to Savara?

Summary

How does Amarin compare to Avalyn Pharma?

Summary

How does Amarin compare to Schrodinger?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amarin (AMRN) Competitors

AMRN vs. CAPR, MGTX, SVRA, AVLN, and SDGR

How does Amarin compare to Capricor Therapeutics?

Does the media favor AMRN or CAPR?

Is AMRN or CAPR more profitable?

Which has higher valuation & earnings, AMRN or CAPR?

Which has more risk & volatility, AMRN or CAPR?

Do analysts prefer AMRN or CAPR?

Do institutionals and insiders have more ownership in AMRN or CAPR?

Summary

How does Amarin compare to MeiraGTx?

Is AMRN or MGTX more profitable?

Do analysts rate AMRN or MGTX?

Which has stronger earnings & valuation, AMRN or MGTX?

Do insiders and institutionals have more ownership in AMRN or MGTX?

Which has more volatility and risk, AMRN or MGTX?

Does the media refer more to AMRN or MGTX?

Summary

How does Amarin compare to Savara?

Which has stronger valuation and earnings, AMRN or SVRA?

Do insiders & institutionals have more ownership in AMRN or SVRA?

Is AMRN or SVRA more profitable?

Do analysts prefer AMRN or SVRA?

Which has more risk and volatility, AMRN or SVRA?

Does the media refer more to AMRN or SVRA?

Summary

How does Amarin compare to Avalyn Pharma?

Do institutionals and insiders have more ownership in AVLN or AMRN?

Is AVLN or AMRN more profitable?

Do analysts recommend AVLN or AMRN?

Which has higher earnings and valuation, AVLN or AMRN?

Does the media prefer AVLN or AMRN?

Summary

How does Amarin compare to Schrodinger?

Does the media prefer SDGR or AMRN?

Do analysts recommend SDGR or AMRN?

Which has more volatility and risk, SDGR or AMRN?

Do institutionals & insiders have more ownership in SDGR or AMRN?

Is SDGR or AMRN more profitable?

Which has preferable earnings & valuation, SDGR or AMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools